1 June 2018 in Drug Design, Development and Therapy
Purpose: Pancreatic carcinoma is the neoplasia with the major mortality, and main standard treatments in this cancer increase survival but do not lead to complete recovery of the patient. The aim of this study was to evaluate the efficacy of Abraxane® (nab-paclitaxel) in Italian patients with metastatic pancreatic cancer (MPC). Patients and methods: We conducted a retrospective analysis of 80 patients. Overall survival (OS) was the primary end point for evaluating the efficacy of nab-paclitaxel in combination with gemcitabine treatment, while carbohydrate antigen 19-9 (CA 19-9) reduction, safety, progression-free survival (PFS), overall response rate and reduction in pain were secondary end points. Results: The median OS was 8 months, and the median PFS was 5 months. A considerable difference in CA 19-9 before and after treatment was observed. Descriptive and correlation analyses were done to examine the relationship between CA 19-9 response and OS. Linear regression analysis between OS and CA 19-9 response revealed that CA 19-9 is an important predictor of OS, showing a positive correlation. Conclusion: Nab-paclitaxel is a well-tolerated and effective treatment for patients affected by MPC. The drug showed an improved tolerability profile, significant pain relief and an increase in survival rate.
3 January 2024 in Epigenomics
18 September 2017 in Annals of Oncology
Background: Long non-coding RNAs (lncRNAs) are emerging as essential regulators of genetic and epigenetic networks. Their deregulation may underlie carcinogenesis suggesting their potential involvement in tumorigenic and metastatic processes, as well as their role as prognostic/predictive biomarkers for clinical use in patients with several solid tumors. Few studies evaluated lncRNAs expression in rare tumors such as Gastrointestinal Stromal Tumors (GISTs). Indeed, the upregulation of HOTAIR has been associated with tumor aggressiveness and metastasis, and poor survival of GIST patients. In order to gain more detailed insight on the molecular role of lncRNAs, we analyzed the expression levels of lncRNAs H19, MALAT1 and HOTAIR in tissue specimens of surgically resected GIST patients to evaluate the potential role of lncRNAs as prognostic biomarkers.
1 March 2021 in Journal of Thoracic Oncology
1 September 2021 in Annals of Oncology
Breast cancer susceptibility genes 1 and 2 (BRCA 1/2) pathogenic germline variants (gPV) are involved in an increased cumulative risk for cancers (above all breast and ovarian cancers). Overweight/obesity is a well-known systemic condition conferring higher cancer risk too.